HitGen Reports Steady Growth in First Three Quarters of 2026, with Q3 Results Maintaining Year-on-Year Upward Trend Release Time：2026-10-28

Chengdu, China, October 28, 2026 – After market close on October 28, HitGen Inc. (SSE: 688222.SH, hereinafter referred to as “HitGen” or the “Company”) announced financial results for the first three quarters of 2026. In the first three quarters of 2026, HitGen sustained steady growth in revenue, profit, and gross margin. The Company recorded revenue of 549.98 million yuan, up 48.73% year on year, and net profit attributable to shareholders of the company of 139.42 million yuan, up 50.11% year on year. In the third quarter alone, the Company achieved revenue of 204.00 million yuan, up 42.88% year on year, and net profit attributable to shareholders of the company of 58.74 million yuan, up 37.15% year on year, maintaining a steady upward trend. Since the beginning of 2026, HitGen has actively expanded its customer base at home and abroad, with new and existing commercial projects continuing to progress and being delivered on schedule, while its new business model has steadily advanced toward commercialization, driving year-on-year revenue growth across all business segments. Profit growth was underpinned by higher revenue and improved gross margin; excluding the impact of foreign exchange losses, total profit for the first three quarters would reach 168.60 million yuan. In addition, the Company’s R&D investment increased significantly in the first three quarters, with a focus on advancing the in-house pipelines such as HG146 and HG254, and developing core technology platforms including DEL, cyclic peptidomimetics library, RIPTAC, and delivery systems, thereby laying a solid foundation for future commercialization and long-term development.

Forward-Looking Statements: The report may contain certain "forward-looking statements" that are intended for information purpose only and does not constitute investment advice to you, or any form of financial opinion or recommendation by the Company. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH) is dedicated to building a world-class innovative biopharmaceutical enterprise. Driven by the mission to advance human health and quality of life, it provides innovative therapeutic solutions to address unmet medical needs. Centered on its internationally leading DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics, and has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery and optimization engine that delivers both therapeutics molecules and tool molecules to the global pharmaceutical industry. Headquartered in Chengdu, China, HitGen maintains subsidiaries in Cambridge, UK, and Houston, USA, with its operational network spanning the globe. Through diversified and flexible business models including technical services, project out-licensing and product sales, the Company has forged extensive collaborations with a broad range of pharmaceutical and biotechnology companies, chemical firms, foundations, and research institutions. As of June 30, 2026, it has empowered over 700 clients globally and contributed to thousands of their innovative drug development projects. HitGen also advances multiple internal programmes at various clinical and preclinical stages. For more information, please visit www.hitgen.com.